CERS - Cerus Corp Stock Price, Fair Value and News

$1.580.00 (0.00%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

CERS Price Action

Last 7 days

-7.6%

Last 30 days

-4.8%

Last 90 days

-12.2%

Trailing 12 Months

-29.1%

CERS RSI Chart

CERS Valuation

Market Cap

293.4M

Price/Earnings (Trailing)

-14.9

Price/Sales (Trailing)

1.55

EV/EBITDA

-32.77

Price/Free Cashflow

-27.66

CERS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

CERS Fundamentals

CERS Revenue

Revenue (TTM)

186.8M

CERS Earnings

Earnings (TTM)

-19.7M

Earnings Growth (Yr)

59.63%

Earnings Growth (Qtr)

49.19%

CERS Profitability

EBT Margin

-10.50%

Return on Equity

-36.81%

Return on Assets

-10.39%

Free Cashflow Yield

-3.62%

CERS Investor Care

Shares Dilution (1Y)

2.49%

Diluted EPS (TTM)

-0.11

CERS Alerts

ARK Investment Management LLC reported owning 12.27% of CERS [2024-11-12]
Big jump in Earnings (Y/Y)
Losses in recent quarter

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	187.9M	187.6M	187.2M	186.8M
2022	0	0	0	188.3M
2021	116.2M	120.6M	126.5M	159.5M
2020	95.0M	96.7M	98.9M	114.2M
2019	0	76.3M	79.0M	135.9M
2018	50.1M	48.3M	44.8M	79.7M
2017	36.6M	36.8M	37.5M	43.6M
2016	34.2M	34.6M	36.7M	37.2M
2015	36.2M	36.5M	34.2M	34.2M
2014	37.8M	36.2M	36.1M	36.4M
2013	37.7M	38.7M	41.0M	39.7M
2012	33.1M	35.6M	36.1M	36.7M
2011	22.1M	23.0M	25.7M	30.6M
2010	0	19.2M	20.4M	21.7M
2009	0	0	0	18.0M

Get all data in R, Python etc through our Historical Stock Data APIs

About Cerus Corp

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

CEO	Mr. William M. Greenman
WEBSITE	cerus.com
SECTOR	Healthcare
INDUSTRY	Medical Devices
EMPLOYEES	665

Cerus Corp Frequently Asked Questions

What is the ticker symbol for Cerus Corp? What does CERS stand for in stocks?

CERS is the stock ticker symbol of Cerus Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Cerus Corp (CERS)?

As of Fri Dec 20 2024, market cap of Cerus Corp is 293.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CERS stock?

You can check CERS's fair value in chart for subscribers.

Is Cerus Corp a good stock to buy?

The fair value guage provides a quick view whether CERS is over valued or under valued. Whether Cerus Corp is cheap or expensive depends on the assumptions which impact Cerus Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CERS.

What is Cerus Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, CERS's PE ratio (Price to Earnings) is -14.9 and Price to Sales (PS) ratio is 1.55. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CERS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Cerus Corp's stock?

In the past 10 years, Cerus Corp has provided -0.128 (multiply by 100 for percentage) rate of return.